✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No actionable change — this is a reply letter in an ongoing academic debate about rimegepant trial methodology; clinicians should monitor the primary literature for resolution of this interpretive dispute.
✦ Why It Matters ✦
The exchange highlights unresolved methodological questions about how to analyze acute vestibular migraine treatment trials, which matter for how audiologists and vestibular specialists interpret future rimegepant evidence.
✦ Key Points ✦
- 01Reply letter in Cephalalgia responding to criticism of rimegepant trial interpretation.
- 02Debate centers on whether baseline severity or treatment timing drove the observed results.
- 03No new primary data is presented in this reply.
- 04Rimegepant targets the CGRP pathway implicated in migraine.
- 05The ongoing exchange may influence how future vestibular migraine trials are designed.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
The original study's findings on rimegepant for vestibular migraine remain valid despite the critique about baseline severity and treatment timing.
opinionunclear✦ Research metadata ✦
- PMID
- 42615633
- DOI
- 10.1177/03331024261474833.
- Journal
- Cephalalgia
- Publication type
- editorial
- Evidence level
- 5
- Population
- Adults with vestibular migraine treated acutely with rimegepant
- Intervention
- Rimegepant (acute treatment for vestibular migraine)
Primary outcomes
Rebuttal of baseline severity vs. treatment timing confound critique